Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, provides an overview of allogeneic chimeric antigen receptor (CAR) T-cell therapies in development. He describes ATA3219, a novel anti-CD19 CAR-T cell therapy developed for B-cell malignancies, as well as ATA2271, a mesothelin-targeted CAR-T immunotherapy for solid tumors. Tabelecleucel is an additional CAR-T cell therapy that treats Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) following hematopoietic cell or solid organ transplantation. This interview took place at Meeting on the Mesa 2021.
The current landscape of allogeneic CAR T-cell therapies
Теги
Speaker: Pascal TouchonInstitution: Atara BiotherapeuticsEvent: Meeting on the Mesa 2021Format: InterviewSpecialty: OncologySpecialty: HematologyField: Immuno-OncologyField: TreatmentMedicines: ATA2271Medicines: TabelecleucelMedicines: ATA3219Technology: Cell TherapyTechnology: CAR T-Cell TherapyTechnology: Autologous TherapyTechnology: Allogeneic TherapySubject: Solid TumorsSubject: Post-Transplant Lymphoproliferative DiseaseCAR-T cell
![Python - Полный Курс по Python [15 ЧАСОВ]](https://s2.save4k.org/pic/cfJrtx-k96U/mqdefault.jpg)
